Abstract
To the Editor: We wish to report another case of parkinsonism associated with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP).1 2 3 A previously healthy 25-year-old man was admitted to another hospital in an immobile, mute state. His girlfriend stated that over eight days he had gradually become withdrawn and had stopped talking and eating. He had a long history of drug abuse. Routine laboratory examination of the cerebrospinal fluid, a CT head scan, and an electroencephalogram were normal. The patient was diagnosed as having an acute psychotic state with catatonia, and he was treated with haloperidol in a psychiatric facility.He did not improve appreciably, and . . .